Renalys Pharma is a clinical-stage biopharmaceutical company developing therapeutics for renal disease in Asian patients.
Renalys Pharma has raised $38.5M in total funding. The most recent round was Series A. The last funding was announced in July 2024.
Renalys Pharma's investors include SR One, Japan Post Bank Asset Management, Nippon Venture Capital, Catalys Pacific, Sumitomo Mitsui Trust Bank.
Renalys Pharma is headquartered in Tokyo, Japan.
Renalys Pharma is a clinical-stage biopharmaceutical company developing therapeutics for renal disease in Asian patients.
Renalys Pharma is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Renalys Pharma — Funding & Investors." VCBacked, July 17, 2024, https://www.vcbacked.co/company/renalys-pharma. Accessed August 14, 2026.
VCBacked. (2024). Renalys Pharma — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/renalys-pharma
{{cite web |title=Renalys Pharma — Funding & Investors |url=https://www.vcbacked.co/company/renalys-pharma |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated